| Literature DB >> 28596426 |
Adam T Hill1,2, Charles S Haworth3,2, Stefano Aliberti4, Alan Barker5, Francesco Blasi4, Wim Boersma6, James D Chalmers7, Anthony De Soyza8, Katerina Dimakou9, J Stuart Elborn10, Charles Feldman11, Patrick Flume12, Pieter C Goeminne13,14, Michael R Loebinger15, Rosario Menendez16, Lucy Morgan17, Marlene Murris18, Eva Polverino19, Alexandra Quittner20, Felix C Ringshausen21, Gregory Tino22, Antoni Torres19, Montserrat Vendrell23, Tobias Welte21, Rob Wilson15, Conroy Wong24, Anne O'Donnell25,26, Timothy Aksamit27,26.
Abstract
There is a need for a clear definition of exacerbations used in clinical trials in patients with bronchiectasis. An expert conference was convened to develop a consensus definition of an exacerbation for use in clinical research.A systematic review of exacerbation definitions used in clinical trials from January 2000 until December 2015 and involving adults with bronchiectasis was conducted. A Delphi process followed by a round-table meeting involving bronchiectasis experts was organised to reach a consensus definition. These experts came from Europe (representing the European Multicentre Bronchiectasis Research Collaboration), North America (representing the US Bronchiectasis Research Registry/COPD Foundation), Australasia and South Africa.The definition was unanimously approved by the working group as: a person with bronchiectasis with a deterioration in three or more of the following key symptoms for at least 48 h: cough; sputum volume and/or consistency; sputum purulence; breathlessness and/or exercise tolerance; fatigue and/or malaise; haemoptysis AND a clinician determines that a change in bronchiectasis treatment is required.The working group proposes the use of this consensus-based definition for bronchiectasis exacerbation in future clinical research involving adults with bronchiectasis.Entities:
Mesh:
Year: 2017 PMID: 28596426 DOI: 10.1183/13993003.00051-2017
Source DB: PubMed Journal: Eur Respir J ISSN: 0903-1936 Impact factor: 16.671